Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
|Articles|January 1, 2004
- Volume 0 0
Women Are Shortchanged on Getting Shut-Eye
Advertisement
Articles in this issue
almost 23 years ago
GER Is Common Among Children with Bronchial Asthmaalmost 23 years ago
Not All GERD Patients Are Alikealmost 23 years ago
Chronic Constipation Makes Headlinesalmost 23 years ago
Dyspepsia and Gastric Emptying in Diabeticsalmost 23 years ago
New Indications: 2003almost 23 years ago
Can You Read These Rxs? Answersalmost 23 years ago
Compounding Hotlinealmost 23 years ago
Sleep Apnea Is Tied to Depression?almost 23 years ago
RLS Runs in the Familyalmost 23 years ago
Case Studies AnswersAdvertisement
Related to this article
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
5